ResMed (RMD)
(Delayed Data from NYSE)
$197.04 USD
-11.30 (-5.42%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $197.20 +0.16 (0.08%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth D Momentum B VGM
Brokerage Reports
ResMed Inc. [RMD]
Reports for Purchase
Showing records 501 - 520 ( 531 total )
Company: ResMed Inc.
Industry: Medical - Products
Q4 CY2013 Feltl CPAP Project 2005-2013: 13,000+ patient survey
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: ResMed Inc.
Industry: Medical - Products
Company: ResMed Inc.
Industry: Medical - Products
Q3 CY2013 Feltl CPAP Project 2005-2013: ~12,000 patient survey
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: ResMed Inc.
Industry: Medical - Products
Company: ResMed Inc.
Industry: Medical - Products
Q2 CY2013 Feltl CPAP Project 2005-2013: ~12,000 patient survey
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: ResMed Inc.
Industry: Medical - Products
Beats on EPS, but mask growth hides, maintain HOLD lower PT to $45
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: ResMed Inc.
Industry: Medical - Products
Q1 CY2013 Feltl CPAP Project 2005-2013: ~12,000 patient survey
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: ResMed Inc.
Industry: Medical - Products
The horse has plenty of puff - ResMed beats top- and bottom-line estimates
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: ResMed Inc.
Industry: Medical - Products
Q4 CY2012 Feltl CPAP Project 2005-2012: 11,000+ patient survey
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: ResMed Inc.
Industry: Medical - Products
Q1 FY2013 EPS ahead of expectations, sales fall short of estimates
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: ResMed Inc.
Industry: Medical - Products
Q2 CY2012 Feltl CPAP Project 2005-2012: 11,000+ patient survey
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: ResMed Inc.
Industry: Medical - Products
Q2 CY2012 Feltl CPAP Project 2005-2012: 10,000+ patient survey
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: ResMed Inc.
Industry: Medical - Products
RMD ResMed beats handily, margin expansion continued; raising rating to BUY, PT to $38
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: ResMed Inc.
Industry: Medical - Products
Company: ResMed Inc.
Industry: Medical - Products
RMD Quantifying the Medicare CPAP supplier widespread prepayment review
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: ResMed Inc.
Industry: Medical - Products
Medical Device-notes from first annual Irvine/San Diago " Bus Tour "This report contains brief updates on the following: ELGX, DXCM, CYTX, GPRO, NUVA, RMD, ALR, MASI, SGNT. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: CAPSTONE INVESTMENTS
Analyst: PUTNAM J
Company: ResMed Inc.
Industry: Medical - Products
Company: ResMed Inc.
Industry: Medical - Products
RMD ResMed Q2 FY2012: High end products awaken margin expansion
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Company: ResMed Inc.
Industry: Medical - Products
Company: ResMed Inc.
Industry: Medical - Products
Feltl and Company Best Ideas 2012
Provider: FELTL & COMPANY